NAPLES, Fla., May 12, 2021 /PRNewswire/ -- Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),
a patient-first biotechnology company developing novel cannabinoid
medicines to improve quality of life for cancer
patients, announced today that it has appointed Arash Asher, M.D., Director of Cancer
Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center,
to the Company's Scientific Advisory Board.
"We believe that Dr. Asher's decision to join Enveric's
Scientific Advisory Board gives the Company a significant advantage
given his extensive time and expertise at Cedars-Sinai," said
David Johnson, Chairman and CEO,
Enveric Biosciences. "Our mission at Enveric is focused on
improving cancer patients' quality of life through leveraging the
power of cannabinoid medicines. Dr. Asher's deep knowledge of
chemotherapy-induced peripheral neuropathy and more should help us
achieve this goal of bringing safe, effective care to cancer
patients who continue to suffer from their treatment side
effects."
Dr. Asher's affiliations with Cedars-Sinai also include serving
as Associate Professor in the Departments of Medicine and Physical
Medicine and Rehabilitation. His clinical and research interests
focus on rehabilitating cancer patients to help restore their
maximal functional capacity and quality of life. Additionally, Dr.
Asher's expertise is in the non-pharmacologic management of pain,
cancer-related fatigue, cognitive dysfunction, neuropathy, exercise
prescription for cancer patients and other musculoskeletal
problems.
Dr. Asher completed a physical medicine and rehabilitation
residency at the UCLA / West Los
Angeles Veterans Affairs program, as well as a cancer
rehabilitation fellowship at the MD Anderson Cancer Center. He is
board-certified by the American Board of Physical Medicine and
Rehabilitation and Hospice and Palliative Medicine.
Additional members of Enveric's Scientific Advisory Board
include:
- Michael J. Zelefsky, M.D. –
Professor of Radiation Oncology in the Department of Radiation
Oncology, and Chief, Brachytherapy Service, at Memorial Sloan
Kettering Cancer Center, with a specialization in clinical
research
- Angus Dalgleish, M.D.
FMedSci – Foundation Professor of Oncology at St Georges', University of London. Principal of the Institute of Cancer
Vaccines and Immunotherapy (ICVI)
- James Perry, M.D. –
Neuro-Oncologist, Sunnybrook Research Institute, and Professor,
University of Toronto, with a
specialization in clinical research
- Zvi Vogel, Ph.D. –
Professor at the Neurobiology Department of the Weizmann Institute,
with a specialization in Cannabinoid research, as well as a patent
contributor
Enveric Biosciences held its first Scientific Advisory Board
meeting on April 25, 2021, during
which the Board discussed and reviewed Enveric's radiodermatitis
and glioblastoma clinical development plans in detail. The group
supported the Company's plan and the identification of ways to
accelerate its research and development programs focused on
cannabinoids as a supportive care therapy.
About Enveric Biosciences
Enveric Biosciences is a
patient-first biotechnology company developing rigorously tested,
novel cannabinoid medicines to improve quality of life for cancer
patients. Initial indications include radiodermatitis, a common and
often severe side effect of radiation therapy, and
chemotherapy-induced neuropathy. For more information, please visit
https://www.enveric.com/.
Forward-Looking Statements
This press release contains
forward-looking statements and forward-looking information within
the meaning of applicable securities laws. These statements relate
to future events or future performance. All statements other than
statements of historical fact may be forward-looking statements or
information. Generally, forward-looking statements and information
may be identified by the use of forward-looking terminology such as
"plans", " expects" or "does not expect", "proposed", "is
expected", "budgets", "scheduled", "estimates", "forecasts",
"intends", "anticipates" or "does not anticipate", or "believes",
or variations of such words and phrases, or by the use of words or
phrases which state that certain actions, events or results may,
could, would, or might occur or be achieved. Forward-looking
statements consist of statements that are not purely historical,
including any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking
statements are based on the beliefs of management as well as
assumptions made by and information currently available to
management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including, but not limited to, the impact of the
novel coronavirus (COVID-19) on Enveric's ongoing and planned
clinical trials; the geographic, social and economic impact of
COVID-19 on Enveric's ability to conduct its business and raise
capital in the future when needed; delays in planned clinical
trials; the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; Enveric's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to Enveric's products, including
patent protection. A discussion of these and other factors,
including risks and uncertainties with respect to Enveric, is set
forth in Enveric's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Investor Contacts
Valter
Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Caitlin
Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com
View original
content:http://www.prnewswire.com/news-releases/enveric-biosciences-appoints-dr-arash-asher-to-scientific-advisory-board-301289310.html
SOURCE Enveric Biosciences